Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: Comparison of two high-throughput testing strategies

Vox Sanguinis

Volumn 84, Issue 1, 2003, Pages 11-19

  Mison, L ^a   Seed, C R ^a   Margaritis, A R ^a   Hyland, Catherine A ^a,b   Minassian, S ^b   Joel, N ^b   Bolton, W V ^b   Brown, S ^b   Whitson, K ^b   Tacey, J ^b   Kiely, P ^b   Stewart, Y ^b   Morrison, J ^b   Cowley, N ^b  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b NONE

Author keywords

Anti HCV antibody; Blood screening; NAT; Seroconversion

Indexed keywords

VIRUS RNA;

ALGORITHM; ARTICLE; AUTOMATION; BLOOD DONOR; CONTROLLED STUDY; DEVICE; EQUIPMENT; GENE TECHNOLOGY; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; PRIORITY JOURNAL; QUALITY CONTROL; SAMPLE; SCREENING; VIRUS DETECTION; VIRUS TRANSCRIPTION; VOLUNTEER;

AUSTRALIA; BLOOD DONORS; DIAGNOSTIC ERRORS; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0038523827     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00246.x     Document Type: Article

References (32)

1. Stramer SL, Caglioti S, Strong DM: NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165-1168
2. Roth WK, Weber M, Seifried E: Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999; 353:359-363
3. Reesink HW, Cuypers HT, Lelie PN: Implementation of HCV-NAT testing in the Netherlands. Dev Biol Stand 2000; 102:105-107
4. Eiras A, Franco E, Hernandez J, Ibarra A, Montoro J, Muncunill J, Planelles D, Sauleda S, Sedeno M, Vesaga M, Villaescusa R: HCV screening in blood donations using RT-PCR in mini-pool: experience in Spain after 20 months routine use. Transfusion 2001; 41(Suppl.):83S SP157
5. Grant PR, Sims CM, Krieg-Schneider F, Love E, Eglin R, Tedder RS: Automated screening of blood donations for hepatitis C RNA using the Qiagen BioRobot 9604 and the Roche COBAS HCV Amplicor assay. Vox Sang 2002; 82:169-176
6. International Forum: Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology. Vox Sang 2002; 82:87-111
7. Busch M: Closing the window on viral transmission; in Stramer SL (ed.): Blood Safety in the New Millennium. Bethesda, AABB Press, 2001:33-54
8. Kleinman SH, Busch MP: The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract Res Clin Haematol 2000; 13:631-649
9. Seifried E, Roth WK: Yield of HCV, HBV and HIV-1 NAT screening at the Red Cross Blood Transfusion Service centers in Germany. Transfusion 2001; 41(Suppl.):9S (Abstract)
10. Saldanha J, Lelie N, Heath A: Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999; 76:149-158
11. Ludicone P, Miceli M, Carapellotti A, Urso P, Mannella E: Validation of TMA assay for HIV detection by using WHO HIV-1 RNA international standard. Transfusion 2001; 41(Suppl.):85S SP 167 (Abstract)
12. Lelie PN, van Drimmelen HA, Cuypers HT, Best SJ, Stramer SL, Hyland C, Allain JP, Moncharmont P, Defer C, Nubling M, Glauser A, da Silva Cardoso M, Viret JF, Lankinen MH, Grillner L, Wirthmuller U, Coste J, Schottstedt V, Masecar B, Dax EM: Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002; 42:527-536
13. Fang C, Vargo J, Smith K, Mimms L, Stramer SL, Caglioti S, Gilbert D, Richards W, Gammon R: Correlation between nucleic acid testing (NAT) and serology in routine blood screening. Transfusion 2001; 41(Suppl.):81s (Abstract)
14. Mison LM, Young IF, O'Donoghue M, Cowley N, Thorlton N, Hyland CA: Prevalence of hepatitis C virus and genotype distribution in an Australian volunteer blood donor population. Transfusion 1997; 37:73-78
15. Muller-Breitkreutz K: Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance. Vox Sang 2000; 78:149-157
16. McAuley J, Williams R, Robertson G, Ellerson K, Caglioti S: Examining failure points within NAT testing. Transfusion 2001; 41(Suppl.):81S: SP 151
17. Gonzalez R, Barea L, Bueno J, Castro E: Implementation of an HIV/HCV nucleic acid testing (NAT) on single donation samples in a 45-000 donations-a-year blood centre. Transfusion 2001; 41(Suppl.):83S: SP 159 (Abstract)
18. Peoples BG, Preston SB, Tzeng JL, Stramer SL, Gifford L, Wissel ME: Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient. Transfusion 2000; 40:1280-1281
19. Durand F, Beauplet A, Marcellin P: Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor. Ann Intern Med 2000; 133:74-75
20. Cardoso MS, Koerner K, Kubanek B: Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: preliminary results. Transfusion 1998; 38:905-907
21. Brojer E, Liszewski G, Niznik A, Rosiek A, Letowska M, Peterson JE, Calmann M, Kerrison PL, Lee SR: Detection of HCV core antigen in HCV RNA positive, anti-HCV negative blood donations from Polish blood donors. Transfusion 2001; 41:304
22. Araujo FM, Henriques I, Monteiro F, Meireles E, Koch MC, Celeste R, Cunha-Ribeiro LM: The first case of HCV seroconversion in Portugal after the introduction of HCV NAT screening. Transfusion 2001; 41:848-849
23. Kleinman S, Stramer S, Mimms L, Phelps B, Gallarda J, Fang C, Busch M: Comparison of preliminary observed yield of HCV and HIV minipool (MP) nucleic acid testing (NAT) with predictions from the incidence/window period (INC/WP) model. Transfusion 2000; 40(Suppl.):S6-S030A (Abstract)
24. Busch M, Giachetti C, Conrad A, Gallarda J, Mimms L, Peddada L, Raia S, Fiebig E, Wright D: Dynamics of HCV viremia during early HCV infection: implications for minipool (MP) vs individual donation (ID) nucleic acid amplification testing (NAT). Transfusion 2000; 40(Suppl.):25S: S90-S040A (Abstract)
25. Fiebig E, Heldebrant C, Smith R, Conrad A, Wright D, Kleinman S, Busch M: HIV viremia preceding antibody (AB) seroconversion (SC): detection of P24Ag (AG), minipool nucleic acid amplification tests (MP-NAT) and individual donation (ID) NAT. Transfusion 2000; 40:25S: S89-S040A (Abstract)
26. Peddada L, Heldebrant C, Smith R, Conrad A, Raia S, Fiebig E, Busch M: HBV viremia preceding HBsAg positivity: implications for minipool (MP) and individual donation (ID) HBV nucleic acid testing (NAT). Transfusion 2000; 40(Suppl.):14-15S (Abstract)
27. Kleinman SH, Busch MP: HBV amplified and back in the blood safety spotlight. Transfusion 2001; 41:1081-1085
28. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, Chamberland ME, Busch MP, Folks TM, Kalish ML: Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000; 284:210-214
29. ABC: First post-NAT transfusion-transmitted AIDS case reported. America's Blood Centres Newsletter 2002; 7:1-2
30. Strainer S, Porter R, Brodsky JP: Sensitivity of HIV and HCV RNA detection by pooled genome amplification testing (GAT). Transfusion 1998; 38(Suppl.):70S (Abstract)
31. Macioszek J, Martinez A, Tidd J, Binder A, Coffman B, Sun G, Truog B, Boyd R, Hoover B, Lidgard G, Shimei T, Webb M, Giachetti C, McDonough S, Mimms L, Clark S, Dahlen T: Performance of the Chiron Procleix HIV-1/HCV assay on the prototype TIGRIS instrument platform. Transfusion 2001; 41(Suppl.):84S (Abstract)
32. Linnen J, Ho-Sing-Ioy M, Miyano M, Kolk D, Broulik A, Menez A, Vaughn A, Petersen E, Shyamata V, Arcangel P, Chien D, Phelps B, Mimms L, Giachetti C: Performance of the TMA Triplex assay which simultaneously detects HIV-1, HCV and HBV nucleic acid. Transfusion 2001; 41(Suppl.):82S: SP 155 (Abstract)